Ysios Capital launches €100 million Biotech creation fund
Spanish venture capital firm Ysios Capital has announced the launch of its new €100 million InceptionBio fund, a vehicle dedicated to the creation and early development of cutting-edge Biotech startups across Europe. The fund aims to bridge the gap between academic research and market-ready companies by actively building and backing new ventures from the ground up.
Focus on company creation and early-stage Biotech
The InceptionBio fund is designed as a company-creation platform rather than a traditional late-stage investment fund. It will identify promising scientific discoveries in areas such as therapeutics, molecular biology, and drug discovery, then assemble founding teams, provide seed capital, and support them through the earliest phases of development.
By concentrating on pre-seed and seed-stage opportunities, Ysios Capital aims to address a persistent funding bottleneck that often leaves high-potential research stranded in laboratories. The firm plans to work closely with universities, research institutes, and hospital innovation units to source breakthrough technologies suitable for company formation.
Strengthening Europe’s life sciences ecosystem
The launch of InceptionBio underlines Spain’s growing role in the European life sciences and venture capital landscape. The fund is expected to create a new wave of Biotech companies that can attract follow-on funding from international investors and accelerate the translation of research into clinical and commercial impact.
Industry observers note that specialized funds like InceptionBio are increasingly critical for Europe to remain competitive in biopharmaceutical innovation. By combining capital with hands-on venture building, Ysios Capital is positioning itself as a key architect of the next generation of European Biotech champions.
The €100 million vehicle adds to the firm’s existing portfolio of life science funds and signals continued confidence in the long-term value of Biotech innovation, despite broader volatility in the global funding environment.